Opthea (NASDAQ:OPT - Get Free Report) is expected to release its H2 2025 results before the market opens on Friday, September 5th. Analysts expect Opthea to post earnings of ($0.0456) per share and revenue of $0.0650 million for the quarter. Interested persons can find conference call details on the company's upcoming H2 2025 earningreport page for the latest details on the call scheduled for Thursday, September 18, 2025 at 8:00 PM ET.
Opthea Price Performance
NASDAQ:OPT remained flat at $3.41 during trading hours on Friday. The business has a 50 day simple moving average of $3.41 and a two-hundred day simple moving average of $3.49. Opthea has a 12-month low of $1.79 and a 12-month high of $6.30.
About Opthea
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
